tetano
Editor, Senior Moderator
Proc Natl Acad Sci U S A
. 2023 Jun 20;120(25):e2207210120.
doi: 10.1073/pnas.2207210120. Epub 2023 Jun 12. An inducible hACE2 transgenic mouse model recapitulates SARS-CoV-2 infection and pathogenesis in vivo
Kuo Liu[SUP] 1 2 [/SUP], Muxue Tang[SUP] 2 [/SUP], Wei Xu[SUP] 3 [/SUP], Xinfeng Meng[SUP] 2 4 [/SUP], Hengwei Jin[SUP] 2 [/SUP], Maoying Han[SUP] 2 4 [/SUP], Jing Pu[SUP] 3 [/SUP], Yutang Li[SUP] 3 [/SUP], Fanke Jiao[SUP] 3 [/SUP], Ruilin Sun[SUP] 5 [/SUP], Ruling Shen[SUP] 6 [/SUP], Kathy O Lui[SUP] 7 [/SUP], Lu Lu[SUP] 3 [/SUP], Bin Zhou[SUP] 1 2 4 [/SUP]
Affiliations
The classical manifestation of COVID-19 is pulmonary infection. After host cell entry via human angiotensin-converting enzyme II (hACE2), the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus can infect pulmonary epithelial cells, especially the AT2 (alveolar type II) cells that are crucial for maintaining normal lung function. However, previous hACE2 transgenic models have failed to specifically and efficiently target the cell types that express hACE2 in humans, especially AT2 cells. In this study, we report an inducible, transgenic hACE2 mouse line and showcase three examples for specifically expressing hACE2 in three different lung epithelial cells, including AT2 cells, club cells, and ciliated cells. Moreover, all these mice models develop severe pneumonia after SARS-CoV-2 infection. This study demonstrates that the hACE2 model can be used to precisely study any cell type of interest with regard to COVID-19-related pathologies.
Keywords: COVID-19; SARS-CoV-2; hACE2 transgenic model; lineage tracing; pneumonia.
. 2023 Jun 20;120(25):e2207210120.
doi: 10.1073/pnas.2207210120. Epub 2023 Jun 12. An inducible hACE2 transgenic mouse model recapitulates SARS-CoV-2 infection and pathogenesis in vivo
Kuo Liu[SUP] 1 2 [/SUP], Muxue Tang[SUP] 2 [/SUP], Wei Xu[SUP] 3 [/SUP], Xinfeng Meng[SUP] 2 4 [/SUP], Hengwei Jin[SUP] 2 [/SUP], Maoying Han[SUP] 2 4 [/SUP], Jing Pu[SUP] 3 [/SUP], Yutang Li[SUP] 3 [/SUP], Fanke Jiao[SUP] 3 [/SUP], Ruilin Sun[SUP] 5 [/SUP], Ruling Shen[SUP] 6 [/SUP], Kathy O Lui[SUP] 7 [/SUP], Lu Lu[SUP] 3 [/SUP], Bin Zhou[SUP] 1 2 4 [/SUP]
Affiliations
- PMID: 37307455
- DOI: 10.1073/pnas.2207210120
The classical manifestation of COVID-19 is pulmonary infection. After host cell entry via human angiotensin-converting enzyme II (hACE2), the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus can infect pulmonary epithelial cells, especially the AT2 (alveolar type II) cells that are crucial for maintaining normal lung function. However, previous hACE2 transgenic models have failed to specifically and efficiently target the cell types that express hACE2 in humans, especially AT2 cells. In this study, we report an inducible, transgenic hACE2 mouse line and showcase three examples for specifically expressing hACE2 in three different lung epithelial cells, including AT2 cells, club cells, and ciliated cells. Moreover, all these mice models develop severe pneumonia after SARS-CoV-2 infection. This study demonstrates that the hACE2 model can be used to precisely study any cell type of interest with regard to COVID-19-related pathologies.
Keywords: COVID-19; SARS-CoV-2; hACE2 transgenic model; lineage tracing; pneumonia.